<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04350645</url>
  </required_header>
  <id_info>
    <org_study_id>UKM PPI/1118/JEP-2019-846</org_study_id>
    <nct_id>NCT04350645</nct_id>
  </id_info>
  <brief_title>Role of Prophylactic Tranexamic Acid in Reducing Blood Loss During Elective Caesarean Section for Placenta Praevia Major</brief_title>
  <official_title>Role of Prophylactic Tranexamic Acid in Reducing Blood Loss During Elective Caesarean Section for Placenta Praevia Major: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Kebangsaan Malaysia Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiti Kebangsaan Malaysia Medical Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prophylactic tranexamic acid will reduce blood loss during Caesarean section for placenta
      praevia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tranexamic acid is a promising agent, easy to administer, cheap, and can be added to the
      other routine management in hospitals deliveries. This study aims to document the efficacy of
      intravenous tranexamic acid in reducing blood loss during and after caesarean section in
      placenta praevia major patients and to assess the Hb and platelet change after its
      administration.

      General objective:

      To investigate the effect of prophylactic IV tranexamic acid in reducing blood loss during
      Caesarean section for placenta praevia major

      Specific objectives:

        1. To evaluate the effect of prophylactic IV tranexamic acid in reducing blood loss during
           Caesarean section up to 2 hours after Caesarean section.

        2. To evaluate the drop in Haemoglobin level postoperatively with the use of prophylactic
           IV tranexamic acid for Caesarean section for PP major

        3. To examine the effect of tranexamic acid on platelet level for caesarean section for PP
           major

        4. To observe the side effects of tranexamic acid

      This study will be conducted at University Kebangsaan Malaysia Medical Centre (UKMMC).
      Patients who meet the inclusion criteria will be invited to participate in the study. Patient
      will be given the information sheet regarding the study and consent will be taken if
      agreeable to participate. Patients' demographic data will be recorded.

      Patients will be classified randomly into two groups using a computer-generated randomization
      system (Microsoft Office Excel). The list of randomization will be concealed and numbered on
      sealed opaque envelopes. Each number will be given a readily prepared 10ml syringe of
      colourless solution, which could either contain the tranexamic acid or placebo.

      Each patient will be assigned a serial identification number. The data will be analysed using
      the Statistical Package for Social Sciences (SPSS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2020</start_date>
  <completion_date type="Anticipated">December 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of prophylactic IV tranexamic acid in amount of blood loss during Caesarean section in placenta previa major</measure>
    <time_frame>24 hours</time_frame>
    <description>Amount of blood loss in mls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the effect of prophylactic IV tranexamic acid in the changes of haemoglobin during Caesarean section in placenta previa major</measure>
    <time_frame>24 hours</time_frame>
    <description>changes of haemoglobin level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the side effects of tranexamic acid</measure>
    <time_frame>one week</time_frame>
    <description>platelet count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hemorrhage From Placenta Previa, With Delivery</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tranexamic acid group will receive 1g slow bolus of tranexamic acid over 2 minutes at least 5 minutes before skin incision (at the end of spinal/general anaesthesia)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo group will receive normal saline 0.9% (same amount as the tranexamic acid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid injection</intervention_name>
    <description>1g slow bolus of tranexamic acid over 2 minutes</description>
    <arm_group_label>Tranexamic acid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline 0.9%</intervention_name>
    <description>10mls normal saline 0.9% over 2 minutes</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all placenta previa major pregnant women

        Exclusion Criteria:

          1. Any cardiac disorder or liver disease

          2. Patient on anticoagulant therapy

          3. History of allergy to tranexamic acid

          4. Any contraindication for tranexamic acid
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kah Teik Chew</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKM Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kah Teik Chew</last_name>
    <phone>+60391455951</phone>
    <phone_ext>5951</phone_ext>
    <email>drchewkt@ukm.edu.my</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universiti Kebangsaan Malaysia Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kah Teik Chew</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiti Kebangsaan Malaysia Medical Centre</investigator_affiliation>
    <investigator_full_name>Chew Kah Teik</investigator_full_name>
    <investigator_title>Clinical lecturer and gynaecologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Previa</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

